Immunotherapy maintenance shows promise in NSCLC

Results from a phase III trial have shown that tecemotide is no more effective than placebo as maintenance therapy in patients with non-small-cell lung cancer.
Source: MedWire News - Lung Cancer - Category: Cancer & Oncology Source Type: news